Does Cosentyx Reduce Vaccine Protection?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system that contribute to vaccine responses. Clinical data shows it can lower antibody production after certain vaccinations, potentially reducing protection, especially for non-live vaccines like influenza or pneumococcal.[1][2]
A phase 3b trial in psoriasis patients found that Cosentyx reduced geometric mean antibody titers by about 20-30% for the seasonal influenza vaccine compared to placebo, though most patients still achieved protective levels.[1] For the pneumococcal vaccine (PPSV23), seroprotection rates dropped from 64% (placebo) to 48% on Cosentyx.[2] Live vaccines like MMR or varicella are contraindicated due to infection risk.[3]
How Does Cosentyx Affect Specific Vaccines?
- COVID-19 vaccines: Real-world studies indicate Cosentyx patients mount weaker but often sufficient neutralizing antibody responses to mRNA vaccines (e.g., Pfizer/Moderna). Seroconversion rates are ~80-90% vs. 95%+ in healthy controls, with boosters helping restore protection.[4]
- Influenza and pneumococcal: Consistent titer reductions (15-40%), but breakthrough infections remain rare if baseline immunity exists.[1][2]
- Tetanus/diphtheria/HPV: Minimal impact on long-term protection in most studies.[5]
Guidelines recommend vaccinating before starting Cosentyx or during treatment for non-live vaccines, prioritizing high-risk patients.[3]
What Happens If You Get Vaccinated on Cosentyx?
Immune responses vary by vaccine type, dose timing, and patient factors like age or comorbidities. Post-vaccination testing (e.g., antibody titers) may be needed for immunocompromised patients to confirm protection. No evidence shows complete loss of efficacy for killed/subunit vaccines, but efficacy wanes faster.[4][5]
Recommendations from Doctors and Guidelines
The American College of Rheumatology advises completing vaccinations 2-4 weeks before biologics like Cosentyx. Avoid live vaccines during treatment and for 3 months after stopping. Monitor high-risk patients (e.g., elderly, diabetics) with titer checks.[3][6]
Timing Vaccines Around Cosentyx Treatment
Start non-live vaccines 4+ weeks before first dose if possible. If already on therapy, vaccinate anyway—response is blunted but present. Pause Cosentyx 1-2 weeks around vaccination only if infection risk is high, per prescriber.[3]
Patient Experiences and Real-World Risks
Reports from psoriasis forums and registries note fewer infections post-vaccination on Cosentyx vs. untreated, but some describe breakthrough flu or COVID despite shots. No large-scale data links Cosentyx directly to vaccine failure deaths.[4]
Sources
[1] JAMA Dermatol, 2017 (influenza trial)
[2] Ann Rheum Dis, 2018 (pneumococcal)
[3] Cosentyx prescribing information, Novartis
[4] Rheumatology, 2021 (COVID-19)
[5] ACR guidelines, 2021
[6] ACR vaccination guidance